2TADDEI S, GHIADONI L, VIRDIS A, et al. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired NO availability in essential hypertensive patients [J]. Circulation, 1999, 100 (13): 1400-1405.
3MIYAZAKI H, MATSUOKA H, COOKE JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis [J].Circulation, 1999, 99 (9): 1141-1146.
4GHIADONI L, TADDEI S, VIRDIS A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension [J]. Hypertension, 1998, 32 (1) :25-32.
5TADDEI S, VIRDIS A, GHIADONI L, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients [J]. J Hypertens, 2001, 19(8) :1379-1386.
6TADDEI S, VIRDIS A, GHIADONI L, et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications [J].Drugs, 2002, 62 (2) :265-284.
7MUIESAN ML, SALVETTI M, MONTEDURO C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension [J]. Hypertension, 1999, 33 ( 1 Pt 2 ): 575-580.
8MCCORMACK PL, WAGSTAFF AJ. Lacidipine: a review of its use in the management of hypertension[J]. Drugs, 2003, 63 (21):2327-2356.
9PERTICONE F, CERAVOLO R, MAIO R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [J]. Cardiovasc Res,1999, 41 (1) :299-306.
10HORNIG B, LANDMESSER U, KOHLER C, et al. Comparative effect of ace inhibition and angiotensin Ⅱ type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase [J]. Circulation, 2001, 103(6) :799-805.
